---
title: "KeyBanc downgrades AT&T (T) to a Sell"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271674500.md"
description: "KeyBanc analyst Brandon Nispel has downgraded AT&T (T) to a Sell with a price target of $20.00. This follows a similar Sell rating from Arete Research's Andrew Beale. Despite these downgrades, Citi maintained a Buy rating on AT&T in December. Nispel has an average return of 4.5% and a 51.41% success rate on his stock recommendations."
datetime: "2026-01-06T14:35:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271674500.md)
  - [en](https://longbridge.com/en/news/271674500.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271674500.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271674500.md) | [繁體中文](https://longbridge.com/zh-HK/news/271674500.md)


# KeyBanc downgrades AT&T (T) to a Sell

In a report released today, Brandon Nispel from KeyBanc downgraded AT&T to a Sell, with a price target of $20.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Nispel covers the Communication Services sector, focusing on stocks such as AT&T, Comcast, and Cogent Comms. According to TipRanks, Nispel has an average return of 4.5% and a 51.41% success rate on recommended stocks.

In addition to KeyBanc, AT&T also received a Sell from Arete Research’s Andrew Beale in a report issued today. However, on December 22, Citi maintained a Buy rating on AT&T (NYSE: T).

### Related Stocks

- [AT&T Inc. (T.US)](https://longbridge.com/en/quote/T.US.md)

## Related News & Research

- [At&t chief executive John Stankey agreed to the new terms for the FirstNet program last week - WSJ](https://longbridge.com/en/news/281237372.md)
- [AT&T CTO Details 5G and Fiber Expansion Plans, AI Network Push, and Satellite Direct-to-Cell Outlook](https://longbridge.com/en/news/280886993.md)
- [KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)](https://longbridge.com/en/news/281676928.md)
- [NiSource started at overweight by KeyBanc on 'doing data center growth the right way'](https://longbridge.com/en/news/281233537.md)
- [This Brinker International Analyst Turns Bullish On Chili's Sales](https://longbridge.com/en/news/281548036.md)